Cancer vaccines using AI gets research funding
The University of Oxford has secured Medical Research Council funding to advance AI-driven cancer vaccine research, leveraging the UK’s sovereign AI supercomputers Dawn and ISAMBARD-AI. The project, led by Dr Lennard Lee, aims to develop personalized mRNA cancer vaccines by analyzing tumor biology and testing AI predictions in patient samples, with support from UKRI, ARIA, and Cancer Research UK.
The University of Oxford has received funding from the Medical Research Council (MRC) to accelerate research into AI-powered personalized cancer vaccines. The UK Cancer Vaccine AI & Supercomputing Project, led by consultant medical oncologist Dr Lennard Lee, will use the UK’s most powerful AI supercomputers, Dawn and ISAMBARD-AI, to analyze vast amounts of cancer and immune data. The project brings together over 2,500 scientists, clinicians, technologists, and patients to develop vaccines tailored to individual tumors. At its core is CIARA, an AI platform designed to study tumor biology, coordinate experiments, and predict effective vaccine targets. The MRC funding will support the manufacture of experimental mRNA cancer vaccines and test whether AI-selected targets trigger strong immune responses in patient samples. The team previously gained access to Dawn in August, enabling high-scale data analysis beyond conventional university computing. Dr Lee emphasized the UK’s capability in sovereign AI systems, stating the project has rapidly advanced personalized drug development. Additional support comes from UK Research and Innovation (UKRI), the Advanced Research and Invention Agency (ARIA), and Cancer Research UK. The goal is to determine if AI-driven vaccine targets can generate effective anti-cancer immune responses, offering hope for more precise cancer treatments.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.